EBIT: Income before interest and taxes.
Oncotelic Therapeutics, Inc. (OTLC) had EBIT of $-3.19M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$249.28M |
|
-- |
|
-- |
|
$3.19M |
|
$-3.19M |
|
$363.76M |
|
$360.57M |
|
$360.57M |
|
$249.02M |
|
$249.02M |
|
$249.02M |
|
$249.02M |
|
|
EBIT |
$-3.19M |
$-2.99M |
|
422.23M |
|
422.23M |
|
$0.59 |
|
$0.59 |
|
| Balance Sheet Financials | |
$1.20M |
|
-- |
|
$391.89M |
|
$393.09M |
|
$18.14M |
|
$1.66M |
|
$113.21M |
|
$131.36M |
|
$261.73M |
|
$258.94M |
|
$261.73M |
|
442.60M |
|
| Cash Flow Statement Financials | |
$-1.38M |
|
-- |
|
$1.39M |
|
$0.11M |
|
$0.11M |
|
$0.00M |
|
$2.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.07 |
|
-- |
|
-- |
|
0.01 |
|
0.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
95.15% |
|
96.17% |
|
63.35% |
|
94.54% |
|
$0.59 |
|
$-0.00 |
|
$-0.00 |
|